Oral semaglutide versus injectable glucagon-like peptide-1 receptor agonists: a cost of control analysis

For the treatment target of HbA1c ≤6.5%, costs of control were USD 15,430 for once-weekly semaglutide 1 mg and USD 17,383 for oral semaglutide 14 mg per patient achieving the target.

• Once-weekly semaglutide 1 mg and oral semaglutide 14 mg had the lowest annual treatment costs per patient achieving HbA1c ≤6.5%.
• For the HbA1c <7.0% target, once-weekly semaglutide 1 mg was associated with the lowest cost of control at USD 12,627, followed by oral semaglutide 14 mg at USD 13,493.
• All other GLP-1 receptor agonists compared had higher costs of control for both HbA1c targets.
• Oral semaglutide 14 mg may be cost-effective compared to dulaglutide, exenatide (both weekly and twice daily), liraglutide, and lixisenatide for glycemic control.

AI simplified